Emergent BioSolutions Inc. (EBS)
| Market Cap | 368.14M -25.8% |
| Revenue (ttm) | 770.20M -9.6% |
| Net Income | -176.80M |
| EPS | -3.39 |
| Shares Out | 51.27M |
| PE Ratio | n/a |
| Forward PE | 10.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 654,821 |
| Open | 6.96 |
| Previous Close | 6.91 |
| Day's Range | 6.84 - 7.23 |
| 52-Week Range | 4.36 - 14.06 |
| Beta | 2.29 |
| Analysts | Buy |
| Price Target | 11.00 (+53.2%) |
| Earnings Date | Nov 2, 2026 |
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for EBS stock is "Buy." The 12-month stock price target is $11.0, which is an increase of 53.20% from the latest price.
News
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the t...
Russian plague outbreak could boost these under-the-radar pharma stocks
Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irk...
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing res...
Emergent BioSolutions Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Leading in biodefense and opioid overdose solutions, the company reported strong financial results for 2026, reduced debt, and expanded its international footprint. Ongoing innovation and a robust pipeline address emerging threats, while operational restructuring enhances efficiency.
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875...
Emergent BioSolutions announces $24M modification from BARDA
Emergent BioSolutions (EBS) announced a contract modification valued at approximately $24M from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Pre...
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Re...
Emergent awarded standing offer by Government of Canada for Narcan Nasal Spray
Emergent BioSolutions (EBS) announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply Narcan Nasal Spray. The standing offer...
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitiv...
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awarene...
Emergent BioSolutions reinstated with an Underweight at JPMorgan
JPMorgan reinstated coverage of Emergent BioSolutions (EBS) with an Underweight rating and no price target The company is in a transition phase, with the recent setback from increasing competition in…
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $EBS--EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law.
EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions
Emergent BioSolutions cut its FY2026 adjusted EBITDA outlook to $130-$150 million from $155-$175 million amid continued NARCAN pricing and margin pressure, with NARCAN gross margin having fallen to 1...
Emergent BioSolutions price target lowered to $10 from $12 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Emergent BioSolutions (EBS) to $10 from $12 and keeps a Buy rating on the shares. The company reported a revenue beat and…
Emergent BioSolutions Earnings Call Transcript: Q2 2026
Q2 2026 results exceeded expectations with strong MCM revenue and disciplined execution, but naloxone market competition led to a downward revision in full-year guidance and a $191 million non-cash impairment. Restructuring actions target $40 million in annualized savings.
Emergent BioSolutions Earnings release: Q2 2026
Emergent BioSolutions released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Emergent BioSolutions Slides: Q2 2026
Emergent BioSolutions has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Emergent BioSolutions Quarterly report: Q2 2026
Emergent BioSolutions has published its Q2 2026 quarterly earnings report on August 5, 2026.
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as all...
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2026.
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time to discuss the financial...
Emergent BioSolutions awarded $52.7M contract modification
Emergent BioSolutions (EBS) announced it has been awarded a contract modification valued at $52.7M from the Administration for Strategic Preparedness and Response, or ASPR, at the United States Depart...
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for St...
BioMendics Receives FDA Fast Track Designation for BM-3103 (TolaSure® Gel™) for Epidermolysis Bullosa Simplex
AKRON, Ohio--(BUSINESS WIRE)-- #BIO2026--BioMendics, LLC, a clinical-stage biotechnology company developing innovative therapies for rare genetic skin disorders, today announced that the U.S. Food and...
Emergent BioSolutions Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company leads in biodefense and opioid overdose treatments, reporting a successful turnaround with improved EBITDA, cash flow, and debt reduction. Growth is driven by product innovation, international expansion, and major government contracts, with a strong focus on R&D and capital efficiency.